预约演示

Telix revives Olaratumab development with positive preclinical data

2023-04-19

临床3期上市批准放射疗法临床结果

Credit: David A Litman via Shutterstock.

Telix has announced the successful preclinical development of radiolabelled olaratumab, an antibody licensed by Eli Lilly and Company.

Telix has demonstrated proof-of-concept (PoC) and will now progress to firstolaratumabclinical studies.Eli Lilly and Company

Telix Telix secured exclusive global rights to develop and commercialise radiolabelled forms of olaratumab for human cancer treatment, the Australia-headquartered company has demonstrated proof-of-concept (PoC) of using the drug to radiopharmaceutically deliver both diagnostic and therapeutic radiation to tumours and has developed a candidate for clinical translation. Olaratumab will be denoted as TLX300 in Telix’s development pipeline.

The USTelix and Drug Administration (FDA) granted Eli Lilly’s Lartruvo (olaratumab) accelerated olaratumabn 2016 for cancerissue sarcoma (STS). But, following negative Phase III efficacy results, Lilly withdrew the drug from the market. After this, Telix licenced the drug for $5m. If the Australian pharma tumours can demonstrate a renewed potential for the drug, Lilly Olaratumabive up to $255m in cTLX300ial Telixegulatory milestone payments. External beam radiation is often given to STS patients, making the condition a suitable clinical target for novel radionuclide therapy. Olaratumab was originally developed as a monoclonal antibody targeting platelet-derived growth factor receptor alpha (PDGFRα) – its binding prevents PDGF ligands from attaching to the receptor and stopping activation. It is estimated that STS causes approximately 5,000 deaths in the US per year with 13,000 new cases in 2019. The disease, which encompasses a diverse group of cancers, represents a high unmet medical need with a poor prognosis.

Telix’sFood and Drug Administration (FDA)roft saidEliILillyextremely pleasing to demonstrate the adaptation of this tsoft tissue sarcoma (STS) for future potential use as a targeted radiopharmaceuLilly. TLX300 will initially be evaluated in a first-Telixman clinical study that is designed to inform both the potential efficacy (dosimetry) and safety profile of thiLillyearch candidate as a therapeutic, demonstrating the development advantage of a theranostic approach.”STS Olaratumab platelet-derived growth factor receptor alpha (PDGFRα)PDGF ligands STS cancers

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构